治疗埃博拉病毒疾病的最新进展:简要概述
L'Emir Wassim El Ayoubi1, Omar Mahmoud2, Johnny Zakhour3
1Division of Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
PLoS pathogens
|March 15, 2024
概括
埃博拉病毒病 (EBOD) 具有很高的死亡风险. 最近的进展包括FDA批准的治疗方法和针对扎伊尔埃博拉病毒 (EBOV) 的疫苗,为这种致命威胁提供了新的希望.
科学领域:
- 病毒学和传染病学.
- 公共卫生和流行病学.
- 医疗疗的医学疗法.
背景情况:
- 埃博拉病毒病 (EBOD) 构成了严重的全球健康威胁,特别是在非洲国家,死亡率在25%至90%之间.
- 最近在乌干达爆发的苏丹埃博拉病毒 (SUDV) 疫情 (2022-2023) 凸显了EBOD持续存在的危险,EBOD是由十年来未见过的一种物种引起的.
- 从历史上看,EBOD管理一直依赖于支持性护理,治疗选择有限,直到最近的突破.
研究的目的:
- 审查EBOD的临床表现,传播和支持性护理.
- 探索EBOD治疗剂和疫苗的最新进展.
- 为了突出开发治疗扎伊尔埃博拉病毒 (EBOV) 和其他物种的进展.
主要方法:
- 关于EBOD管理,治疗和预防的文献综述.
- 分析最近的疫情及其病因因素.
- 检查已批准的治疗单克隆抗体和疫苗.
主要成果:
- 两种单克隆抗体 (Ebanga和Inmazeb) 在2020年获得FDA批准用于EBOV治疗.
- 针对EBOV的疫苗Ervebo在2019年获得了FDA的批准.
- 在开发向疗法和预防性疫苗方面取得了重大进展.
结论:
- 在开发针对性治疗和针对EBOD的疫苗方面取得了重大进展,特别是针对扎伊尔埃博拉病毒 (EBOV).
- 持续的研究和开发对于应对SUDV和其他埃博拉病毒物种的威胁至关重要.
- 已批准的治疗方法和疫苗的可用性代表了管理和预防EBOD的范式转变,改善了患者的治疗结果.
相关概念视频
00:42Cross-reactivity
Overview
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:24Smallpox
Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
01:18Yellow Fever
Yellow fever is a viral hemorrhagic disease caused by the yellow fever virus (YFV), a member of the Flaviviridae family. It is transmitted primarily by Aedes and Haemagogus mosquitoes in tropical and subtropical regions of Africa and South America. After transmission through a mosquito bite, the virus initially replicates in skin-resident immune cells such as dendritic cells and macrophages. These cells then migrate to the lymph nodes, where viral replication increases, eventually leading to...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...